Affordable Care Act led to improved treatment of colorectal cancer among young adults

December 19, 2019

An Affordable Care Act provision that allowed young adults to be covered under their parents' insurance led to a shift to earlier-stage diagnosis and more timely receipt of adjuvant chemotherapy among young colorectal cancer patients, according to a new American Cancer Society study. The study appears in JNCI.

In September 2010, the Dependent Coverage Expansion (DCE) under the Affordable Care Act (ACA) allowed young adults up to age 26 to be covered under their parents' private health insurance. To find out whether the DCE was associated with improved care among young adults with colorectal cancer, investigators led by Leticia Nogueira, Ph.D. analyzed outcomes for nearly 2,000 newly-diagnosed colorectal cancer patients who were DCE-eligible (ages 19 to 25) and compared outcomes to more than 8,000 who were not (ages 27 to 34) using the National Cancer Database during 2007-2013.

They found DCE-eligible patients who had surgery for stage IIB-IIIC colorectal cancer were 34% more likely to receive adjuvant chemotherapy post-ACA than pre-ACA. Furthermore, among DCE-eligible patients, average time from surgery to chemotherapy decreased by 7 days; from 57.4 days pre-ACA to 50.4 days post-ACA. There was no change among the comparison group (those ineligible for DCE). The authors note that because the younger age groups were too young to be eligible for routine colorectal cancer screening, the change likely reflect improved access to care that allows for timely assessment of early symptoms.

"Our results have important implications for young adults diagnosed with colorectal cancer who may experience interruptions in their insurance coverage due to loss of dependent coverage or other life transitions," write the authors. "Our findings highlight the role of the ACA in improving access to potentially life-saving cancer care, including a shift to early-stage diagnosis and more timely receipt of adjuvant chemotherapy."
Article: Improvement in Care among Young Adult Colorectal Cancer Patients Eligible for Dependent Coverage Expansion after the Affordable Care Act. JNCI: Journal of the National Cancer Institute; DOI: 10.1093/jnci/djz235.

URL upon publication:

American Cancer Society

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to